Open-label extension study of leniolisib in activated PI3Kδ syndrome: Long-term efficacy and safety
Leniolisib, a PI3Kδ inhibitor, improves the pathophysiology of APDS. This publication demonstrates the safety and efficacy of leniolisib in patients with APDS ≥12 years of age receiving up to 7 years of treatment, illustrating a positive tolerability profile and sustained disease burden reduction.